Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:743

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $2,000.00
Meta Description Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the
Publisher GlobalData
Date of Report Jun 21, 2011
Quick Overview
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress Disorder (PTSD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 PTSD Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 6
2.3 Etiology and Pathophysiology 8
2.4 Signs and Symptoms 10
2.5 Diagnosis 11
2.6 Treatment and Management Options 12
2.6.1 Referral Pathway 13
2.7 GlobalData Pipeline Report Guidance 14
3 PTSD Therapeutics - Market Characterization 15
3.1 PTSD Therapeutics Market Size (2005 - 2010) - Global 15
3.2 PTSD Therapeutics Market Forecast (2010 - 2017) - Global 16
3.3 PTSD Therapeutics Market Size (2005 - 2010) - The US 17
3.4 PTSD Therapeutics Market Forecast (2010 - 2017) - The US 18
3.5 PTSD Therapeutics Market Size (2005 - 2010) - France 19
3.6 PTSD Therapeutics Market Forecast (2010 - 2017) - France 20
3.7 PTSD Therapeutics Market Size (2005 - 2010) - Germany 21
3.8 PTSD Therapeutics Market Forecast (2010 - 2017) - Germany 22
3.9 PTSD Therapeutics Market Size (2005 - 2010) - Italy 23
3.10 PTSD Therapeutics Market Forecast (2010 - 2017) - Italy 24
3.11 PTSD Therapeutics Market Size (2005 - 2010) - Spain 25
3.12 PTSD Therapeutics Market Forecast (2010 - 2017) - Spain 26
3.13 PTSD Therapeutics Market Size (2005 - 2010) - The UK 27
3.14 PTSD Therapeutics Market Forecast (2010 - 2017) - The UK 28
3.15 PTSD Therapeutics Market Size (2005 - 2010) - Japan 29
3.16 PTSD Therapeutics Market Forecast (2010 - 2017) - Japan 30
3.17 Drivers and Barriers for the PTSD Therapeutics Market 31
3.17.1 Drivers for the PTSD Therapeutics Market 31
3.17.2 Barriers for the PTSD Therapeutics Market 31
3.18 Opportunity and Unmet Need Analysis 31
3.19 Key Takeaway 32
4 PTSD Therapeutics - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the PTSD Therapeutics Market 34
4.3.1 Paxil (paroxetine) 34
4.3.2 Zoloft (sertraline hydrochloride) 34
4.4 Key Takeaway 35
5 PTSD Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 PTSD Therapeutics Pipeline - Pipeline by Phases of Development 36
5.3.1 PTSD Therapeutics - Phase III Pipeline 37
5.3.2 PTSD Therapeutics - Phase II Pipeline 37
5.3.3 PTSD Therapeutics - Phase I Pipeline 37
5.3.4 PTSD Market - Discovery and Pre - clinical Pipeline 37
5.3.5 Technology Trends Analytic Framework 38
5.4 PTSD Therapeutics Market - Clinical Pipeline by Mechanism of Action 40
5.5 Key Takeaway 40
6 PTSD Therapeutics - Clinical Trials Mapping 41
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 41
6.2 Clinical Trials by Phase 42
6.3 Clinical Trials by Trial Status 43
6.4 Prominent Sponsors 44
6.5 Top Companies Participating in PTSD Therapeutics Clinical Trials 46
7 Strategic Assessment 47
7.1 Key Events Impacting the Future Market 47
7.2 PTSD Therapeutics - Implications for Future Market Competition 48
8 PTSD Therapeutics - Future Players 49
8.1 Introduction 49
8.2 Company Profiles 49
8.2.1 Biotie Therapies 49
8.2.2 Sanofi - Aventis 50
8.2.3 Columbia Northwest Pharmaceuticals 53
9 PTSD Therapeutics - Licensing and Partnership Deals 55
10 PTSD Therapeutics - Appendix 56
10.1 Market Definitions 56
10.2 Abbreviations 56
10.3 Methodology 57
10.3.1 Coverage 57
10.3.2 Secondary Research 57
10.3.3 Forecasting 58
10.3.4 Primary Research 60
10.3.5 Expert Panel Validation 60
10.4 Contact Us 60
10.5 Disclaimer 60
10.6 Bibliography 61




...